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Abstract
VML 295 (LY 293111) is a potent and specific
leukotriene4 receptor antagonist. It has pre-
viously been shown in human volunteers
that VML 295 at a dosage of 48 mg twice dai-
ly inhibits the ex vivo leukotriene B4 (LTB4)-
induced upregulation of CD11b on peripheral
blood neutrophils. A clear dose-response re-
latinship was shown. In addition, VML 295
inhibits various inflammatory aspects result-
ing from LTB4 challenge of the skin, again
showing a dose-response relationship. In
view of the large variation in the elimination
half-life of VML 295 (25–88.5 h) in individual
human subjects, the present pharmacologi-
cal study was designed to provide informa-
tion on the pharmacodynamics of the drug
by the assessment of VML 295 plasma con-
centrations, ex vivo LTB4-induced CD11b
upregulation of neutrophils, neutrophil accu-
mulation in the skin following epicutaneous
application of LTB4 and epidermal regenera-
tion following standardized surface trauma.
A group of 36 healthy volunteers were
treated in a double-blind study with VML 295
at 200 mg twice daily, VML 295 at 200 mg
once daily or placebo for 7 days. Before treat-
ment, at the end of treatment and following
discontinuation of treatment, VML 295 plas-
ma concentrations and CD11b upregulation
of blood neutrophils were assessed. In 18
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subjects, the effects of the three treatments
on LTB4-induced inflammatory were as-
sessed before and at the end of treatment,
and in the remaining 18 subjects the effects
of these treatments on epidermal regenera-
tion were assessed similarly. VML 295 at
200 mg either twice or once daily has a pro-
found inhibitory effect on ex vivo LTB4-
induced CD11b upregulation of blood neu-
trophils, LTB4-induced neutrophil accumula-
tion in the skin, trauma-induced hyperprolif-
eration of the epidermis and regenerative
keratinization. The twice daily dose schedule
was significantly more effective than the
once daily regimen in reducing ex vivo
CD11b stimulation of neutrophils, in blood
samples collected 24 h after discontinuation
of VML 295 treatment. The twice daily sched-
ule tended to be more efficient in skin biop-
sies, although this difference was not sta-
tistically significant in the number of sub-
jects investigated. A plasma concentration
of 100 ng/ml proved to be the threshold for
these effects. The profound biological ef-
fects, both systemically and cutaneously, as
well as the safety profile, make VML 295 a
promising drug for skin disorders character-
ized by epidermal proliferation and neutro-
phil accumulation.
Copyright © 2000 S. Karger AG, Basel
Introduction
VML 295 (LY 293111) is a novel diaryl
ether carboxylic acid derivative which has
been characterized as a potent and specific
antagonist at the leukotriene B4 (LTB4) recep-
tor. In vitro, VML 295 demonstrates a range
of pharmacological actions against LTB4-in-
duced human neutrophil stimulation includ-
ing inhibition of chemotactic activity, cal-
cium generation and induction of CD11b/
CD18 adhesion receptor expression [1]. VML
295 also antagonized LTB4- and fMLP-in-
duced human neutrophil aggregation.
VML 295 has been administered to a total
of 211 human subjects and has proven to be
safe and well tolerated with no serious drug-
related adverse events reported.
Single and multiple oral doses of VML 295
have been administered to healthy human
subjects and patients up to a maximum dose
of 200 mg twice daily for 8 weeks. At the high-
est dose, almost complete suppression of ex
vivo human neutrophil LTB4-induced CD11b
upregulation was demonstrated. In an antigen
challenge study in mild asthmatics, 1-week
treatment with VML 295 at 112 mg 3 times
daily resulted in a significant reduction in the
number of neutrophils in bronchoalveolar la-
vage fluid [2]. Additionally, in a study involv-
ing epicutaneous administration of LTB4 in
healthy volunteers, VML 295 demonstrated
(relative to placebo) a significant dose-related
suppression of cutaneous hyperproliferation
and a reduction of inflammatory cell infiltrate
with effects (which were most marked at
200 mg twice daily, although a dosage of
48 mg twice daily already inhibited the ex
vivo LTB4-induced upregulation of CD11b
on peripheral blood neutrophils) on dermal
and epidermal polymorph migration, perivas-
cular T lymphocyte accumulation and Lan-
gerhans cell migration [3].
Previous pharmacology data have indi-
cated the individual subjects’ terminal elimi-
nation half-life to range between 25 and
88.5 h [Vanguard Medica, data on file].
Therefore, a pharmacological study in healthy
volunteers was designed to provide informa-
tion on the pharmacodynamics of VML 295
itself and, in particular, to investigate the
dynamics of the cellbiological effects of this
compound in peripheral blood leukocytes ex
vivo, LTB4-induced cutaneous inflammation
in vivo, and regenerative epidermis in vivo.
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The following study aims were defined: to
evaluate the effects of once daily (o.d.) and
twice daily (b.i.d.) treatments of VML 295 at
200 mg on LTB4-induced upregulation of
CD11b expression in peripheral blood neu-
trophils before, during and 2–36 h after dos-
ing, in healthy volunteers ex vivo; to assess the
effects of o.d. and b.i.d. treatments of VML
295 at 200 mg on elastase-positive cells, pre-
dominantly neutrophils, following epicuta-
neous application of LTB4; and to measure
the effects of o.d. and b.i.d. treatments of
VML 295 at 200 mg on epidermal cell charac-
teristics during regenerative recovery of the
epidermis following adhesive tape-stripping.
Patients and Methods
Subjects, Blood Samples and Biopsies
The design of the present study was a double-blind,
randomized, placebo-controlled, parallel-group phase-
I study. Thirty-six healthy volunteers without a clini-
cally significant medical history were included in this
study, after they had given informed consent. All vol-
unteers were treated with either VML 295 at 200 mg
o.d. (4 active 50-mg capsules before noon and 4 place-
bo capsules after noon), 200 mg b.i.d. (4 active cap-
sules taken twice daily), or placebo (4 placebo capsules
taken twice daily). Randomization was carried out
before using a computerized program for randomiza-
tion. All subjects were treated for 8 days (from day 1 up
to and including day 8). All medications were prohib-
ited 7 days prior to and during the entire study, unless
required for emergency or supportive care. Paraceta-
mol was allowed for minor headaches at the discretion
of the investigator. Women of childbearing age had to
take (oral) contraceptives.
Blood specimens (n = 36) for assessment of ex vivo
neutrophil CD11b surface expression were obtained
on day 1 (immediately prior to the study medication),
day 8 (prior to the last evening medication), and day 9
(2, 12 and 24 h after the last dose of the study medica-
tion). Unfortunately, in subjects in the VML 295
200 mg o.d. group, blood sampling 2 h after the last
dose on day 9 was missed due to an error in the sam-
pling schedule. Peripheral blood (5 ml) was collected
through venipuncture, kept in EDTA at 4 °C and pro-
cessed within 2 h after collection to prevent nonspe-
cific upregulation of CD11b expression as a result of
neutrophil activation.
In one group of 18 volunteers, epicutaneous LTB4
application was carried out, 24 h before day 1 and 24 h
before day 8. The other group of 18 subjects attended
the clinic 48 h prior to both day 1 and day 8 for induc-
tion of the standardized surface trauma by tape-strip-
ping. In all volunteers, two punch biopsies (3 mm)
were taken from affected areas under local anesthesia
on days 1 and 8.
Ex vivo CD11b Integrin Upregulation Assay
Blood samples were processed in triplicate using
90-Ìl aliquots which were incubated with LTB4 (10 Ìl,
1 ! 10–7 M ) in Hanks’ balanced salt solution (HBSS;
Sigma Chemical Corp., St. Louis, Mo., USA) contain-
ing 0.1% bovine serum albumin (HBSS-BSA) for
30 min at 37 °C or with HBSS-BSA alone. Samples
were then cooled and incubated in the dark for 30 min
at 4°C with 10 Ìl (0.045 g/l) anti-human CD11b fluo-
rescein conjugate (Mo-1-FITC; Coulter Corp., Hial-
eah, Fla., USA). Erythrocytes were lysed (with 10%
FACS® Lysing Solution in demineralized water; Bec-
ton Dickinson, San Jose, Calif., USA), and the remain-
ing cells were washed with HBSS-BSA, fixed in 1%
paraformaldehyde solution and stored at 4 °C until
analysis. The analysis was always performed within
one week of preparation of the leukocyte suspensions
in order to prevent the possibility of artefacts caused
by prolonged storage.
All specimens were analyzed with an Epics® Elite
flow cytometer (Coulter, Luton, UK). Cells were ex-
cited with an air-cooled 488-nm Argon laser set at
15 mW. Green fluorescence (FITC) was measured
through a 525-nm band pass filter (band width 30 nm).
Calibration and sensitivity were checked in every ex-
periment by using FITC-labelled beads (Standard-
Brite; Coulter Source, Hialeah, Fla., USA). Forward
and side scatter were used for gating only granulocytes.
For each sample 5,000 gated cells were analyzed.
LTB4 Application and Tape-Stripping
LTB4 (Peasel, Frankfurt, Germany) was adminis-
tered at a dose of 100 ng diluted in 10 Ìl of ethanol,
and applied to the test sites on the upper arm of the
subject using a plastic cylinder (5.5 mm diameter) and
the ethanol evaporated under a stream of nitrogen (n =
18). The test sites were convered with impermeable
dressings (silver patch; van der Bend, Brielle, The
Netherlands) and held in place with leukosilk tape
(Beiersdorf, Hamburg, Germany) after application of
LTB4.
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Tape-stripping was carried out over a 2 ! 2 cm
area of the upper arm of the subject (n = 18) by
repeated application of adhesive tapes (Sellotape). The
procedure was stopped when the skin reached a glisten-
ing appearance. At this moment, the stratum corneum
was virtually totally removed.
Immunohistochemical Staining Procedures
From the biopsies (n = 18) taken 24 h after LTB4
application, cryostat sections of 7 Ìm were cut and
fixed for 10 min in acetone for staining with anti-elas-
tase (IgG1 kappa, clone NP57 mouse; Dakopatts, Co-
penhagen, Denmark). Anti-elastase has a specificity
for neutrophil elastase which is present in PMNs and
sporadic in monocytes. Slides were incubated with the
monoclonal antibody for 30 min, followed by 2 washes
with PBS and incubation for 30 min with rabbit-anti-
mouse antibody conjugated with peroxidase (RAM-
PO, Dakopatts). After 2 more washes with PBS and
preincubation with sodium acetate buffer (pH 4.9),
slides were stained with sodium acetate buffer contain-
ing 200 mg/l 3-amino-9-ethyl-carbazole (AEC solu-
tion) and 0.01% H2O2 for 10 min at 37°C in the dark.
All slides were washed in demineralized water and
lightly counterstained with Mayer’s hematoxylin (Sig-
ma). Slides were finally mounted on glycerol gelatin
(Sigma) and studied by light microscopy.
All stainings were assessed before the study was
unblinded. The density of infiltrate cells was assessed
semi-quantitatively in epidermis and dermis using a
5-point scale and a 7-point scale, respectively: epider-
mis: 0 = no positive cells observed, 1 = sporadic stain-
ing, 2 = minimal presence, 3 = moderate presence, 4 =
pronounced presence; dermis: 0 = no positive cells, 1 =
sporadic, 2 = 1–25% of infiltrate cells stained, 3 = 26–
50%, 4 = 51–75%, 5 = 76–99%, 6 = 100%.
Cell Suspensions and Flow Cytometry
Epidermal cell suspensions were derived from the
biopsies taken 48 h after tape-stripping of the skin (n =
18). Dermoepidermal separation was performed by
overnight incubation with thermolysin, and an epider-
mal cell suspension was prepared by trypsinization
according to standardized procedures [4]. To assess
epidermal proliferation and inflammation, the cell sus-
pensions were stained with the following agents: RKSE
60 (a gift from Prof. F.C. Ramaekers, Department of
Molecular Biology, University of Maastricht, The
Netherlands) which recognizes cells of the suprabasal
compartment, expressing keratin 10 [5]; TOPRO-3-
IODIDE (TB3; Molecular Probes, Eugene, Oreg.,
USA) which allows quantification of the percentages of
cells in S and G2M phases [6], and anti-vimentin
(VIM3B4; Novocastra Laboratories, Newcastle-upon-
Tyne, UK) which is a monoclonal antibody binding to
vimentin [7].
The triple labelling of these two antibodies and
DNA stain have been described before [4]. In brief, 3-
color fluorescence was obtained with the fluoro-
chromes fluorescein-isothiocyanate (FITC) and phy-
coerythrin (PE) which are conjugated to monoclonal
goat antibodies against mouse IgG2a and mouse IgG1,
respectively, in combination with TP3.
From each sample 5,000 gated cells were measured
and analyzed using an EPICSR Elite flow cytometer
(Coulter) equipped with a dual laser system. PE and
FITC were excited with an air-cooled Argon ion laser
(15 mW, 488 nm) and TP3 was excited with a HeNe
laser (10 mW, 633 nm). After setting appropriate gates
with the EPICS® Elite software, the percentages of
vimentin- and keratin-10-positive cells were calcu-
lated. Using MulticycleTM software, the percentages of
basal keratinocytes in the S and G2M phase of the cell
cycle were calculated from the DNA histograms.
Clinical Laboratory Safety Measurements and
VML 295 Plasma Levels
Prior to starting medication, a general physical
examination and laboratory measurement consisting
of hematology, serum chemistry, serum electrolytes,
random blood glucose and urinalysis were performed.
During the study period, the hematology, serum chem-
istry and urinalysis examinations were repeated on
days 1, 8, and at the follow-up visit (between day 9 and
23). On days 4, 8 and 9 (12, 18 and 24 h after dosing),
additional blood samples (10 ml) were taken for assay
of VML 295 concentrations in plasma.
Statistical Analysis
Statistical comparisons were carried out with two-
tailed tests at the 5% level of significance. Compari-
sons between the VML 295 at 200 mg b.i.d. group and
the placebo group were conducted for the CD11b
ratios 2 and 12 h after the last dose using Wilcoxon
rank sum tests with normal approximation. For the
data 24 h after the dose, all three treatment groups
were compared by the Kruskal-Wallis test with the ¯2
approximation. For all time points, the median differ-
ences between treatment groups were estimated from
the analysis and 95% confidence intervals were con-
structed around these estimated differences. The data
obtained from the flow-cytometrical analysis of the cell
suspensions and the data obtained from the immuno-
histochemical assessments were statistically analyzed
by the paired Student t test.
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Fig. 1. Mean CD11b stimulation
ratio (mean B 2 SD) in volunteers
treated with VML 295 once daily
(n = 12), volunteers treated with
VML 295 twice daily (n = 11),
and volunteers treated with place-
bo (n = 13). a Before and during
treatment. b Following discontin-
uation of treatment.
Results
Demographic Characteristics
A total of 36 subjects (20 females and 16
males) were recruited to the study, 12 (33.3%)
were assigned to the VML 295 at 200 mg o.d.
group, 11 (30.6%) to the VML 200 mg b.i.d.
group and 13 (36.1%) to the placebo group. A
total of 35 volunteers completed the study.
One patient dropped out for reason of a gas-
trointestinal (viral) infection. Overall, the av-
erage age of the subjects was 27.1 years, the
youngest subject being 18.1 and the oldest
56.8 years.
Ex vivo CD11b Upregulation of Blood
Neutrophils
Figures 1a and b summarize the mean
CD11b stimulation ratio before, during and
after discontinuation of treatment with VML
295 at 200 mg o.d., 200 mg b.i.d. and placebo.
It can be seen that those subjects who were
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Fig. 2. a VML plasma concentra-
tions during and after discontinua-
tion of VML 295. b CD11b stimu-
lation ratio versus VML 295 plas-
ma concentration.
treated with VML 295 had a markedly re-
duced stimulation ratio during treatment. As
long as 36 h after discontinuation, the stimu-
lation ratio remained reduced. CD11b stimu-
lation ratios were, on average, 0.21-fold great-
er in the o.d. group compared to the b.i.d.
group. At both 2 and 12 h after the final dose
of study medication, the differences between
the VML 295 b.i.d. group and the placebo
group were highly significant (p ! 0.001).
However, from 24 h after discontinuation of
VML 295 onward, the o.d. schedule had per-
mitted a slight recovery in LTB4-induced ex
vivo CD11b stimulation, whereas the b.i.d.
schedule maintained complete inhibition of
the CD11b stimulation. At 24 h after the last
dose, a statistically highly significant differ-
ence was determined between the three treat-
ment groups (p ! 0.001). Pairwise compari-
sons revealed that results from the VML 295
o.d. treatment group and the VML 295 b.i.d.
treatment group were both significantly lower
than those obtained from the placebo group
(p ! 0.001). Comparison between the o.d. and
b.i.d. groups indicated that there was a differ-
ence which was statistically significant (p !
0.012).
VML 295 Plasma Concentrations
VML 295 plasma concentrations were
measured during and following discontinua-
tion of treatment. It can be seen that during
D
ow
nl
oa
de
d 
by
: 
R
ad
bo
ud
 U
ni
ve
rs
ite
it 
Ni
jm
eg
en
    
    
    
    
    
    
  
13
1.
17
4.
24
8.
15
4 
- 1
/3
1/
20
20
 9
:5
8:
47
 A
M
Effects of Leukotriene B4 Receptor
Antagonist (VML 295)
Skin Pharmacol Appl Skin Physiol
2000;13:75–85
81
Fig. 3. Elastase-positive cells 24 h
after epicutaneous application of
LTB4. a Epidermal accumulation
of elastase-positive cells (mean B
SEM). b Dermal accumulation of
elastase-positive cells (mean B
SEM).
treatment (day 8, 2 h after dosing) no overall
correlation could be observed between
CD11b stimulation and plasma VML 295 lev-
els, although the inhibition of the CD11b
upregulation proved to be most apparent
at VML 295 VML plasma concentrations
1100 ng/ml (fig. 2b). Interestingly, 24 h after
discontinuation, a correlation coefficient of
–0.578 (p = 0.008) could be shown between
both parameters.
Elastase-Positive Cells 24 h after
Epicutaneous Application of LTB4
In total, 18 subjects were included for
LTB4 application. In 5 subjects, placebo treat-
ment was given, 6 subjects received VML 295
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o.d. and 7 subjects were treated with VML
295 b.i.d. Both dose regimens of VML 295
completely inhibited infiltration of elastase-
positive cells (p = 0.0005 o.d. and p = 0.002
b.i.d.) into the epidermis following applica-
tion of LTB4 (fig. 3a). The placebo treatment
had no statistically significant effect (p =
0.09). Both dose regimens of VML 295 also
markedly reduced the infiltration of elastase-
positive cells (fig. 3b) into the dermis (p =
0.006 o.d., p = 0.0007 b.i.d.).
Epidermal Cell Characteristics 48 h after
Tape-Stripping
In total, subjects were included for tape-
stripping. Eight subjects were treated with
placebo, 6 subjects with VML 295 o.d. and 4
with VML 295 b.i.d. Both o.d. and b.i.d. VML
295 dose regimens were effective in reducing
the percentage of basal cells (keratin 10-nega-
tive cells) in S and G2M phases (p = 0.006 and
p = 0.04, respectively), whereas placebo had
no effect (p = 0.36) on this parameter. These
results are shown in figure 4a. VML 295 b.i.d.
(fig. 4b) showed a slight trend towards a re-
duction in vimentin-positive cells (p = 0.06),
whereas placebo or VML 295 o.d. showed no
consistent effect (p = 0.29 and p = 0.22,
respectively). Figure 4c shows the percentages
of suprabasal cells (keratin 10-positive cells)
following tape-stripping. Remarkably, place-
bo and VML 295 o.d. did not have any effect
on the relative decrease of suprabasal cells
48 h after tape-stripping (p = 0.47 and p =
0.18, respectively). After VML 295 b.i.d., the
percentage of keratin 10-positive cells is in-
creased 48 h after tape-stripping (p = 0.05), as
compared to their expression after tape-strip-
ping before VML 295 medication.
Safety and Tolerability
The three treatment groups were compara-
ble with respect to vital signs at screening.
There were no clinically significant changes in
vital signs, i.e. none were reported as adverse
events. There were no major changes in labo-
ratory values. A total of 23 adverse events
were reported by 17 (47.2%) subjects. Of
these, 10 events were reported by 7 subjects
(58.3%) in the VML 295 at 200 mg o.d. group,
6 by 4 subjects (36.4%) in the VML 295 b.i.d.
group and 7 by 6 subjects (46.2%) in the pla-
cebo group. The most frequently reported
event was headache, which was reported by 6
subjects, 3 (25%) in the VML 295 o.d. group
and 3 (23.1%) in the placebo group. Diarrhea
was reported by a total of 4 subjects, 2 (16.7%)
in the VML 295 o.d. group and 2 (18.2%) in
the VML 295 b.i.d. group. No serious adverse
events were reported.
Discussion
The present study reconfirms the marked
efficacy of VML 295 in blocking the ex vivo
LTB4-induced upregulation of CD11b on pe-
ripheral blood neutrophils. In a previous
study, this inhibition was shown after 5 days
of treatment with a dose of 200 mg b.i.d. in
healthy volunteers [3].
The present study provides further infor-
mation on the pharmacodynamics of VML
295. The reduction of CD11b upregulation
remained manifest as late as 36 h following
discontinuation of treatment. Interestingly,
the o.d. schedule showed a small diminish-
ment of this profound inhibition of the LTB4-
induced CD11b upregulation 24 h after dis-
continuation of treatment. Therefore, the
b.i.d. schedule was selected for further study
as a more effective dosing regimen for reduc-
tion of neutrophil functioning.
Integration of the observations of VML
295 plasma concentrations and CD11b upreg-
ulation revealed that a concentration of VML
295 of 100 ng/ml is sufficient to cause a sub-
stantial inhibition of neutrophil functioning.
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Fig. 4. Epidermal cell characteris-
tics 48 h after tape-stripping. a Per-
centage of basal cells in SG2M
phase (mean B SEM). b Per-
centage of vimentin-positive cells
(mean B SEM). c Percentage of
keratin 10-positive cells (mean B
SEM).
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It is possible that the lack of correlation be-
tween VML 295 and CD11b upregulation is
caused by a full occupancy of receptors at this
concentration of VML 295.
In order to find to what extent VML 295
might have a pharmacological effect on the
skin and to what extent the advantage of VML
295 b.i.d. is also reflected in an enhanced effi-
cacy on the skin, two quantitative well-repro-
ducible in vivo models for cutaneous inflam-
mation were evaluated. The inflammatory re-
sponse to epicutaneous application of LTB4
has been evaluated extensively [8–10]. LTB4
in ethanol at concentrations between 10 and
100 ng/10 Ìl induces accumulation of neutro-
phils, with a sharp maximum between 16 and
24 h. In this dose range a clear dose-response
relationship has been shown. The response to
tape-stripping has been evaluated before as a
well-reproducible in vivo model to study a
clearly defined wave of recruitment of cycling
epidermal cells and as such is adequate for
studies on the induction of the epidermal pro-
liferation in vivo [4, 11]. Again, the present
study reconfirms these in vivo models as ade-
quate to study the interference of an experi-
mental drug with neutrophil accumulation
and epidermal proliferation, respectively.
The pronounced accumulation of neutro-
phils following the relatively high dose of
100 ng/10 Ìl of LTB4 was totally blocked in
the epidermis by the o.d. and b.i.d. dose
schedule of VML 295, whereas a partial inhi-
bition was observed in the dermis. The b.i.d.
schedule tended to inhibit the dermal accu-
mulation of neutrophils more than the o.d.
schedule, although both schedules were not
statistically significantly different. In a pre-
vious communication [3], VML 295 b.i.d.
was reported to produce a pronounced reduc-
tion of various LTB4-induced inflammatory
events.
The effect of VML 295 on epidermal
growth and differentiation characteristics fol-
lowing tape-stripping further substantiates
the profound effect of VML 295 on epidermal
cell behavior. In a previous study, epidermal
proliferation in vivo proved to be markedly
stimulated following epicutaneous applica-
tion of LTB4. In vitro, LTB4 was shown to
stimulate epidermal proliferation [3]. The
present investigation again suggests that LTB4
has a direct effect on epidermal proliferation.
Although the percentage of vimentin-positive
cells tended to be reduced by VML 295 b.i.d.,
a consistent and profound inhibition of the
percentage of basal cells in the S and G2M
phase and an increase of keratin 10-positive
cells was evident for both the o.d. and b.i.d.
dose schedule of VML 295. The b.i.d. dose
schedule tended to be more effective as com-
pared to the o.d. schedule, although a statisti-
cally significant difference between both
schedules was not shown.
The profound effects of VML 295 on neu-
trophil accumulation and epidermal prolifer-
ation makes this compound an attractive can-
didate for the treatment of skin disorders
characterized by epidermal proliferation and
neutrophil accumulation. In view of the safety
data, so far, further clinical studies are worth-
while.
D
ow
nl
oa
de
d 
by
: 
R
ad
bo
ud
 U
ni
ve
rs
ite
it 
Ni
jm
eg
en
    
    
    
    
    
    
  
13
1.
17
4.
24
8.
15
4 
- 1
/3
1/
20
20
 9
:5
8:
47
 A
M
Effects of Leukotriene B4 Receptor
Antagonist (VML 295)
Skin Pharmacol Appl Skin Physiol
2000;13:75–85
85
References
1 Marder P, Scott Sawyer J, Froelich
LL, Mann LL, Spaethe SM: Block-
ade of human neutrophil activation
by LY293111, a novel leukotriene
B4 receptor antagonist. Biochem
Pharmacol 1995;49:1683–1690.
2 Evans DJ, Barnes PJ, Spaethe SM,
van Alstyne EL, Mitchell MI,
O’Connor BJ: Effect of a leukotriene
B4 receptor antagonist, LY293111,
on allergen induced responses in
asthma. Thorax 1996;51:1178–
1181.
3 van Pelt JP, de Jong EMG, van Erp
PEJ, Mitchell AL, van de Kerkhof
PCM: The regulation of CD11b in-
tegrin levels on human blood leuko-
cytes and leukotriene B4 stimulated
skin by a specific leukotriene B4 re-
ceptor antagonist (LY293111). Bio-
chem Pharmacol 1997;53:1005–
1012.
4 Glade CP, Seegers BAMPA, Meulen
EFJ, van Hooijdonk CAEM, van
Erp PEJ, van de Kerkhof PCM:
Characterization of epidermal cell
suspensions prepared from normal
and hyperproliferative human skin
using an optimized thermolysin-
trypsin protocol. Arch Dermatol
Res 1996;288:203–210.
5 Ramaekers FCS, Puts JJG, Moester
O, Kant A, Huysmans A, Haag D,
Jap PH, Herman CJ, Vooijs GP:
Antibodies to intermediate filament
proteins in the immunohistochemi-
cal identification of human tumors:
An overview. Histochem J 1983;15:
691–713.
6 van Hooijdonk CAEM, Glade CP,
van Erp PEJ: TO-PRO-3 iodide, a
novel HeNe laser-exitable DNA
stain as an alternative for propidium
iodide in multiparameter flow cy-
tometry. Cytometry 1994;17:185–
189.
7 de Waal RMW, Semeijn JT, Corne-
lissen IMH, Ramaekers FCS: Epi-
dermal Langerhans cells contain in-
termediate-sized filaments of the vi-
mentin type: An immunocytologic
study. J Invest Dermatol 1984;82:
602–604.
8 Camp R, Russell Jones R, Brain S,
Woollard P, Greaves M: Production
of intraepidermal microabscesses by
topical application of leukotriene
B4. J Invest Dermatol 1984;82:202–
204.
9 Lammers AM, van de Kerkhof
PCM: Response of polymorphonu-
clear leukocytes to topical leuko-
triene B4 in healthy and psoriatic
skin. Br J Dermatol 1987;116:521–
524.
10 van de Kerkhof PCM, Copius Peere-
boom-Stegeman JHJ, Boeyen J: An
ultrastructural study of the response
of normal skin to epicutaneous ap-
plication of leukotriene B4. J Der-
matol 1991;18:271–278.
11 Boezeman JBM, Bauer FW, de
Grood RM: Flow cytometric analy-
sis of the recruitment of G0 cells in
human epidermis in vivo following
tape stripping. Cell Tissue Kinet
1987;20:99–107.
D
ow
nl
oa
de
d 
by
: 
R
ad
bo
ud
 U
ni
ve
rs
ite
it 
Ni
jm
eg
en
    
    
    
    
    
    
  
13
1.
17
4.
24
8.
15
4 
- 1
/3
1/
20
20
 9
:5
8:
47
 A
M
